Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor
Article in AboutOpen (October 2022)
The most recent citing publications are shown below. View all 18 publications that cite this research output on Dimensions.
Article in AboutOpen (October 2022)
Article in Quality of Life Research (September 2022)
Article in PharmacoEconomics - Open (February 2022)